

Visit Reason: Follow up

## Rio Grande Hematology & Oncology

4391 E. Lohman Ave,  
Las Cruces, NM, 88011  
P: (575) 522-2633 F:(575) 522-2311

Patient Name: Holguin,Irene

Patient DOB: 01/08/1962

Patient Age:61 Y

Patient Sex: female

### Diagnoses

Encounter for antineoplastic chemotherapy - Z51.11

Carcinoma of cervix - C53.9

**Reason for consultation: cervical cancer.**

**Date of consultation/initial visit: 05/12/2023.**

### HPI:

61-year-old female is referred to Medical Oncology for management of cervical cancer.

Pap smear in January showed no abnormal cells were positive high-risk HPV. Subsequent colposcopic exam showed no obvious lesion and endocervical curettage was negative. A week later she had an episode of vaginal bleeding. Because of the bleeding, MRI was performed which showed a suspected neoplastic lesion in the cervix with left adnexal lesion which could have been the pathologic lymph node versus ovarian deposit. Mildly prominent bilateral inguinal lymph nodes and left obturator lymph node which were not enlarged by size criteria. PET-CT scan revealed hypermetabolic activity in the region of the left aspect of the cervix, pelvic lymphadenopathy, hypermetabolic focus corresponding to soft tissue nodule in the region of the left adnexa, likely a lymph node. Initiated on chemoradiation therapy on 06/07/2023.

Patient had abnormal PAP smear in the past , 10 years ago and underwent possible colposcopy. Patient used to get PAP smear regularly up until 2019.

Paternal grandmother with breast cancer and father with prostate cancer.

### Oncologic History:

#### Imaging:

ultrasound of the pelvis, transvaginal on 02/28/2023-uterus measures 5.8 x 3.3 x 3 cm.

Endometrium is 0.3 cm in thickness. 2.4 x 1.4 x 2 cm subtle heterogeneous hypoechoic cervical mass with internal vascularity on Doppler. No evidence of acute pelvic pathology. Cervical mass is indeterminate and further evaluation with contrast enhanced MRI is recommended.

MRI of the pelvis without and with contrast on 03/20/2023- uterus is anteverted measures 6.7 x 2.9 x 4 cm. T2 hyperintense cervical mass in the lower endocervical region expanding the cervix and extending into the anterior as well as the posterior vaginal fornix. Lesion shows restriction on diffusion in the lesion measures 2.5 x 2 x 2.4 cm. Intact low signal of the vaginal wall. Peritoneal reflection is maintained. No suggestion of parametrial fat invasion. 1.4 x 1.1 cm enhancing soft tissue signal intensity nodule in the left adnexa which also shows restricted diffusion , likely a pathologic lymph node versus a deposit within the left ovary. PET-CT scan is recommended.

Mildly prominent bilateral inguinal lymph nodes and left obturator lymph nodes. Not enlarged by size criteria. Distended bladder.

PET-CT scan on 05/31/2023- hypermetabolic left para-aortic lymphadenopathy extending from the level of L3-L4 disc level distally. Enlarged hypermetabolic left common iliac lymph nodes measuring approximately 1.3 cm in diameter SUV of 4.5. Hypermetabolic focus is seen corresponding to the soft tissue nodule in the region of the left adnexa measuring approximately 1.9 x 1.3 cm SUV of 7.4. Hypermetabolic activity in the region of the left aspect of the cervix likely corresponds to patient's known primary cervical neoplasm.

**Pathology:**

Cervical biopsy on 04/19/2023-invasive squamous cell carcinoma, moderately to poorly differentiated. invasive tumor extends to multiple deep and lateral margins of the biopsy. The tumor in not start the med is 7 mm. Lymphovascular invasion is not seen. Tumor cells stained positive for CK 5, P 40, P 16. PDL1 80-89%.

**Labs:**

**Procedures:**

Loop excision of the cervical lesion on 04/19/2023.

**Staging:**

T1b2N1a- stage IIIC1.

**Treatment:**

initiated on concurrent chemoRT on 06/07/2023.

**Interval History:**

Patient is here with her daughter. She reports fatigue. No new medications. Patient is here for lab results. No ER or hospital visits.

**Allergy**

NKDA

**Current Medications**

Ondansetron 8 MG Oral Tablet Disintegrating: 2 Tablet(s) every 8 hours as needed Oral, Start 06/07/2023, End 10/05/2023, Qty 30 Tablet(s) For 30 Day(s) Refill 3

Lisinopril-hydroCHLORothiazide 20-12.5 MG Oral Tablet: 1 Tablet(s) daily Oral

**Past Medications**

Ambien CR 6.25 MG Oral Tablet Extended Release: 1 Tablet(s) daily Oral, Start 06/20/2023, End 07/20/2023, Qty 30 Tablet(s) For 30 Day(s), - Completed by Huerta, Anabel on 06/28/2023

**Medical History**

Hypertension

Cervical cancer.

**Surgical History**

Tonsillectomy

Cesarean Section

**Family History**

Hypertension

- Father

#### Breast Cancer

- Paternal Grand Mother ( over 60 )

#### Systemic lupus erythematosus

- Paternal Grand Mother

#### prostate cancer

- Father ( 50s )

### **Social History**

Tobacco: Never smoker

Alcohol: Stopped at the end of 2023. Used to drink 2-3 beers a week for a long time..

Drug: Denies Usage

### **Ob/Gyn History**

Menarche: 12 years

Postmenopausal: Yes

OB Summary: Total Preg: 2, Full Term 2, C-Section 1, Living 2

### **Review of Systems**

#### **Constitutional:**

*Admits* Fatigue

*Denies* Recent chills , Fever , Weight change and Change in appetite

#### **Eyes:**

*Denies* New Vision Problems , Eye Irritation , Eye Pain and Yellowing of eyes

#### **Ears, nose, mouth, throat:**

*Denies* Nosebleeds , New cold symptoms , New voice changes and New hearing problems

#### **Cardiovascular:**

*Denies* Chest pain , Palpitations and Swelling in extremities

#### **Respiratory:**

*Denies* Cough , Wheezing and Shortness of breath

#### **Gastrointestinal:**

*Denies* Difficulty swallowing , Nausea , Vomiting , Heartburn , Diarrhea , Constipation , Blood in stools , Clay colored stools , Oily stools and Abdominal pain

#### **Genitourinary:**

*Denies* Difficulty urinating and Blood in urine

#### **Musculoskeletal:**

*Denies* New joint pain , Joint swelling , Neck pain and Low back pain

#### **Dermatology:**

*Denies* New skin rash and Skin lesions

#### **Neurologic:**

*Denies* Headaches , Headaches, Loss of consciousness , Dizziness and Seizures

#### **Psychiatric:**

*Denies* Psychiatric problems

#### **Endocrine:**

*Denies* Appetite Changes , Asthenia , Cold Intolerance , Growth , Hair Changes , Heat Intolerance , Hormone Therapy , Libido Change , Polydipsia , Secondary Sexual Development and Sexual Dysfunction

#### **Immunology:**

*Denies* Previous Transfusions , Rh Incompatibility and Transfusion Reaction

### **Vital Signs**

Weight 169 lbs 5 oz, Height 63", BMI 29.99 kg/m sq, Category Overweight, Temp 98.80 F - Temporal, Pulse 82 b/m - Regular - Sitting, Respiration 19 b/m - Normal, BP 100/62 mm/Hg - Sitting - Left Arm - Standard Cuff Size SAO2 94% - Resting - Room Air, - Automatic Recording, Severity of Pain 0

**Comments:** down by 2 lbs sine last visit

ECOG PS 1

Taken on Jun 28, 2023 at 1:14 PM by Ms Gomez, Belen

## **Physical Exam**

### **General**

Findings: Alert, Oriented to self, Oriented to place, Oriented to date, No acute distress

### **Head**

Findings: Normocephalic

### **Eyes**

Findings: Pupils equal

### **Ears, Nose, Mouth, Throat**

Findings: Normal external appearance to ears

### **Neck**

Findings: Supple

### **Lymphatics**

Findings: No cervical lymphadenopathy noted

### **Cardiovascular**

Findings: Regular rate, Regular rhythm, No murmurs appreciated

### **Pulmonary**

Findings: Clear to auscultation in both lung fields

### **Abdomen**

Findings: Soft, Non-tender, Non-distended

### **Back**

Findings: No pain along spine

### **Extremities**

Findings: No swelling in lower extremities

### **Neurologic**

Findings: Alert and oriented to self, Date and location

## **Lab Result**

**Specimen collected on** 06/27/2023 3:41PM

### **06/27/2023 CBCD - CBC + Differential**

WBC4.9 x10E3/uLRange 4.0-11.0

RBC3.92 x10E6/uLRange 4.01-5.47

Hgb11.8 gm/dLRange 12.0-16.0

Hct34 %Range 36-48

MCV87 fLRange 81-101

MCHC34.5 gm/dLRange 31.1-35.5

RDW13.0 %Range 11.0-14.5

Platelets166 x10E3/uLRange 150-400

Diff TypeAuto Diff

Neutrophils67 %

Lymphocytes10 %

Monocytes11 %

Eosinophils12 %

Basophils0 %

Abs. Neutrophil3.3 x10E3/uLRange 1.8-7.0

Abs. Lymphocyte0.5 x10E3/uLRange 1.0-3.4

Abs. Monocyte0.5 x10E3/uLRange 0.2-0.8

Abs. Eosinophil0.6 x10E3/uLRange 0.0-0.3

Abs. Basophil0.0 x10E3/uLRange 0.0-0.1

TRL Tricore Reference Laboratories, 1001 Woodward PI NE, Albuquerque, NM 87102

**Specimen collected on** 06/27/2023 3:41PM

### **06/27/2023 CMP - Comp Metabolic Panel**

Sodium139 mmol/LRange 134-144

Potassium3.6 mmol/LRange 3.5-5.1

Chloride 100 mmol/L Range 98-111  
CO2 28 mmol/L Range 20-30  
Anion Gap 11 mmol/L Range < 18  
Glucose 107 mg/dL Range 60-100  
Impaired fasting glucose (IFG) is defined as a fasting glucose level of 100-126 mg/dL. (ADA Guidelines Diabetes Care 26: (3160-3167) 2003)

BUN 13 mg/dL Range 7-31  
Creatinine 0.90 mg/dL Range 0.50-1.40  
eGFR non-African Am 73 mL/min/1.73m<sup>2</sup> Range >60  
The eGFR is calculated using the 2021 CKD-EPI creatinine equation that does not use a race coefficient.

GFR Comment: An eGFR based on creatinine concentration is only useful when renal function is stable. It is not su

Calcium 8.6 mg/dL Range 8.4-10.4  
Total Protein 6.8 gm/dL Range 6.1-8.2  
Albumin 3.4 gm/dL Range 3.4-4.7  
Globulin 3.4 gm/dL Range 2.4-4.2  
Bilirubin, total 0.7 mg/dL Range 0.3-1.2  
Alk Phos 93 U/L Range 38-150  
AST (SGOT) 13 U/L Range 6-58  
ALT (SGPT) 22 U/L Range 14-67  
TRL Tricore Reference Laboratories, 1001 Woodward PI NE, Albuquerque, NM 87102

**Specimen collected on** 06/27/2023 3:41PM

**06/27/2023 MG - Magnesium**

Magnesium 1.9 mg/dL Range 1.4-2.6  
TRL Tricore Reference Laboratories, 1001 Woodward PI NE, Albuquerque, NM 87102

**Impression:**

1. Stage IIIC1 moderately to poorly differentiated cervical cancer. Initiated on chemoRT on 06/07/2023. Week 4 treatment today. Toxicity- grade 1 anemia, grade 2 lymphocytopenia.
2. Mild eosinophilia- will monitor.

**Discussion:**

Reviewed the findings with the patient and her daughter. Discussed the lab results with the patient. Notified the patient that she will be receiving week for treatment today and will be receiving 2 more treatments. Told the patient that I would see her in 8 weeks for follow-up.

**Recommendation:**

1. Initiated on concurrent chemoradiation therapy on 06/07/2023. Week 4 treatment today.
2. RTC weekly for the treatment.
3. Follow up with me in 8 weeks.
4. Will send antiemetic prescriptions to the pharmacy.
5. Obtain the records from radiation Oncology.
7. Will cut down on the dose of dexamethasone to 4mg.
8. MRI pelvis on 07/03/2023.

**Follow Up**

Recall on 08/23/2023 with Oncology, RGHO

**Lab Order**

07/03/2023  
CBC + Differential (Lab-CBCD) [No Specimen Selected]  
Comp Metabolic Panel (Lab-CMP) [No Specimen Selected]  
Magnesium (Lab-MG) [No Specimen Selected]

Electronically signed by Dr. Medavarapu, Ramadevi on Sunday, July 2, 2023 at 04:40 PM

A handwritten signature in blue ink, appearing to read 'R. Medavarapu', with a long horizontal stroke extending to the right.

---

Rio Grande Hematology and Oncology  
4391 E. Lohman Ave Las Cruces, NM 88011  
575.522.2633 Fax: 575.522.2311

**Rio Grande Hematology and Oncology**

4391 E. Lohman Ave  
Las Cruces NM 88011  
Phone: (575) 522-2633  
Fax: (575) 522-2311

**Irene Holguin**

Female DOB: 01/08/1962 -  
Account: 3409  
720 W Chestnut Ave  
LAS CRUCES, NM 88005  
C: 575 680 8987, H: 575 680 8109

# Lab Requisition

TriCore Labs

**Insurance**

BCBS-NM MCO (Primary)

**Insured Party**

Self

**Policy #**

YIR837806421

**Order # 37051** Client ID: 33126

**Ordering Provider: Medavarapu, Ramadevi 7/3/20**

**Tests**

CBCD CBC + Differential

*Specimen: No Specimen Selected, Volume: 0.00, Date: 7/3/2023 1:00:00PM,  
Diet: Regular, Urgency: Normal*

CMP Comp Metabolic Panel

*Specimen: No Specimen Selected, Volume: 0.00, Date: 7/3/2023 1:00:00PM,  
Diet: Regular, Urgency: Normal*

MG Magnesium

*Specimen: No Specimen Selected, Volume: 0.00, Date: 7/3/2023 1:00:00PM,  
Diet: Regular, Urgency: Normal*

**Diagnoses**

C53.9 Carcinoma of cervix

C53.9 Carcinoma of cervix

C53.9 Carcinoma of cervix

**Please Bill to Insured Party**



Electronically signed by Dr. Ramadevi Medavarapu on Sunday, July 2, 2023 at 4:39 pm

Date	Time	AM PM	Prescriber's Signature	Prescriber's Name Printed	Beeper Number
Date	Time	AM PM	Nurse's Signature	Faxed By	Time Faxed

# Follow Up Reminder

**Dr. Ramadevi Medavarapu**

Rio Grande Hematology and Oncology  
4391 E. Lohman Ave  
Las Cruces NM 88011  
575.522.2633, Fax: 575.522.2311

**Holguin, Irene**

61 Y, Female- DOB:01/08/1962  
Account #: 3409  
Account #: 3409  
720 W Chestnut Ave  
LAS CRUCES, NM 88005  
H: 575.680.8109, C: 575.680.8987

**Subject:** Follow Up Visit

**Follow Up On:** 08/23/2023

**Follow Up In:** 0

**Created By:** Oncology, RGHO